Daiichi Sankyo shows DU-176b results
8 December 2008 00:00 in Scientific
Daiichi Sankyo has revealed the phase II results of its investigational oral Factor Xa inhibitor DU-176b.
The drug, used in once-daily doses of either 30mg or 60mg by patients with non-valvular atrial fibrillation, was found to produce effects of "comparable safety and tolerability" in comparison to those being administered warfarin.
Daiichi Sankyo's results - revealed at the 50th annual meeting of the American Society of Haematology in San Francisco - have given the company "confidence" in its evaluation of doses for a phase III clinical trial, according to Francis Plat, vice-president of clinical development at the Pharma Development division.
"We are hopeful that DU-176b may one day provide the community a safe and convenient treatment in the prevention of stroke in patients with non-valvular atrial fibrillation," he said.
Non-bleeding events described as "major and clinically relevant" for the once-daily dose group were similar to patients taking warfarin, while those in the twice-daily DU-176b dose group reported significantly higher instances.
Daiichi Sankyo has also announced it has set up a subsidiary in Ireland, people looking for science sales jobs
may also be interested to know.
Other news stories from 08/12/2008
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency